|
| 35976058 | Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas. | Neuro Oncol | 2023 |
| 37805627 | Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas. | Nat Commun | 2023 |
| 37860079 | Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas. | Adv Oncol | 2023 |
| 37958397 | Targeting Cytokines and Their Pathways for the Treatment of Cancer. | Cancers (Basel) | 2023 |
| 37847564 | Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. | J Clin Invest | 2023 |
| 37509400 | The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma. | Cancers (Basel) | 2023 |
| 37509316 | Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review. | Cancers (Basel) | 2023 |
| 37841696 | NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. | Neurooncol Adv | 2023 |
| 37503127 | NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy. | bioRxiv | 2023 |
| 37292686 | Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution. | Res Sq | 2023 |
| 37219390 | HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen. | CNS Oncol | 2023 |
| 36949040 | Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. | Nat Commun | 2023 |
| 37115694 | Aspirin and immunotherapy: a Faustian bargain? | J Clin Invest | 2023 |
| 37104042 | Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors. | J Clin Invest | 2023 |
| 37261911 | Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa. | J Clin Invest | 2023 |
| 36652630 | Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. | Mol Cancer Res | 2023 |
| 36647830 | The kynurenine pathway implicated in patient delirium: possible indications for indoleamine 2,3 dioxygenase inhibitors. | J Clin Invest | 2023 |
| 36647828 | Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. | J Clin Invest | 2023 |
| 36399711 | Determining venous thromboembolism risk in patients with adult-type diffuse glioma. | Blood | 2023 |
| 36831427 | A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin. | Cancers (Basel) | 2023 |
| 36705543 | Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. | Neuro Oncol | 2023 |
| 36795563 | Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. | Cell Rep | 2023 |
| 36759517 | FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. | Nat Commun | 2023 |
| 36594466 | Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. | J Clin Invest | 2023 |
| 36250346 | CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. | Int J Cancer | 2023 |
| 36085259 | Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors. | Cytokine Growth Factor Rev | 2023 |
| 34561270 | Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. | Clin Cancer Res | 2022 |
| 35653194 | Immune landscape of a genetically engineered murine model of glioma compared with human glioma. | JCI Insight | 2022 |
| 35405743 | B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. | Mol Cancer Ther | 2022 |
| 35580289 | A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. | Am Soc Clin Oncol Educ Book | 2022 |
| 35433114 | Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. | Oncoimmunology | 2022 |
| 35575067 | A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. | CNS Oncol | 2022 |
| 35784281 | Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. | Front Immunol | 2022 |
| 35487217 | Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. | Cancer Cell | 2022 |
| 35624002 | Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. | Trends Cancer | 2022 |
| 35413115 | Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. | Cancer Immunol Res | 2022 |
| 36428586 | Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. | Cancers (Basel) | 2022 |
| 36497370 | Clinical Management of Supratentorial Non-Skull Base Meningiomas. | Cancers (Basel) | 2022 |
| 35968785 | Functional imaging of immune cell subpopulations in the tumor microenvironment: clinical implications. | J Clin Invest | 2022 |
| 35926816 | Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. | Ann Oncol | 2022 |
| 36382088 | SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression. | Cancer Res Commun | 2022 |
| 35982952 | Artificial intelligence in the radiomic analysis of glioblastomas: A review, taxonomy, and perspective. | Front Oncol | 2022 |
| 36324813 | cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. | F1000Res | 2022 |
| 36011015 | Next Steps for Immunotherapy in Glioblastoma. | Cancers (Basel) | 2022 |
| 35316217 | Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. | JCI Insight | 2022 |
| 35149861 | Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. | Nat Cancer | 2022 |
| 34865083 | Next-Generation Sequencing of a Glioblastoma with True Epithelial Differentiation. | J Neuropathol Exp Neurol | 2022 |
| 34665646 | New Approaches to Glioblastoma. | Annu Rev Med | 2022 |
| 32112296 | Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. | J Neurooncol | 2021 |
| 35937580 | NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors. | Reports (MDPI) | 2021 |